Comparative Evaluation of Success of NeoPutty Mineral Trioxide Aggregate® with Formocresol as Pulpotomy Medicaments in Primary Molars: A Clinical Study

Abstract

Objective This clinical study was aimed to investigate the clinical and radiographic outcomes of NeoPutty MTA® (Nusmile), a novel mineral trioxide aggregate (MTA) pulpotomy material, in primary teeth of children aged 4–6 years. Methods An in vivo study was done in children aged 4–6 years old. A total of 50 primary second molar teeth were included in the study, with 25 of them undergoing treatment with formocresol (FC) and 25 receiving treatment with NeoPutty MTA®. The subjects were divided into two groups for treatment: the first group received a treatment involving a 1:5 dilution of Buckley’s FC. The second group, however, underwent treatment with NeoPutty MTA®. This study employs a meticulous approach to evaluate the impact of different treatments on a significant number of molar teeth, using FC and NeoPutty MTA® as the respective treatment methods. The demographics of the subject pool are well-documented, comprising a balance of male and female participants. The technique employed for pulp removal and the subsequent management of bleeding are outlined, underscoring the thoroughness of the process. Results At 12 months, the NeoPutty MTA® pulpotomy group showed a significantly higher success rate clinically (96%) compared to the FC group (72%) (P < 0.05), but radiographically although NeoPutty MTA® was better (92%) than FC (82%), it was not statistically significant. NeoPutty®-treated teeth exhibited no signs of pain or discomfort and demonstrated better pulp vitality compared to the FC group. Conclusion NeoPutty MTA® demonstrated superior clinical success rates and better radiographic outcomes compared to traditional FC pulpotomy.

Keywords

• children
• formocresol
• neoputty mta
• primary teeth
• pulpotomy